ZTS - Zoetis Inc
(NaN%)
SNP 500
Sell
Gross Profit was Negative
58%
based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 4787.37%
Operating Income turning Positive
Net Income Growth is 5.31%
Earnings Per Share (EPS) Growth is 7.32%
Net Margin is 27.12%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.74
Debt Ratio is 0.67
Current Debt to Net Income Ratio is 2.14
Total Debt to Total Assets Ratio is 0.47
Cash Flow is STRONG
Cash from Operations Growth is 22.76%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Zoetis Inc (ZTS) - https://www.zoetis.com/
Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Kristin Peck
Employees - 13,800
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.